Chinese clinical oncology最新文献

{"title":"Response to DNA-damaging agents and PARP inhibitors in ATM mutated metastatic colorectal cancer: case series.","authors":"Cody Eslinger, Daniel Walden, Mohamad Bassam Sonbol, Daniel Ahn, Christina Wu, Mitesh Borad, Tanios Bekaii-Saab","doi":"10.21037/cco-25-101","DOIUrl":"10.21037/cco-25-101","url":null,"abstract":"<p><strong>Background: </strong>The ataxia-telangiectasia mutated (ATM) gene is central to homologous recombination (HR) repair and cell-cycle checkpoint control. Pathogenic ATM mutations are increasingly recognized in metastatic colorectal cancer (mCRC) and are associated with improved prognosis, with survival nearly twice that of ATM wild-type disease. DNA-damaging chemotherapy combined with poly (ADP-ribose) polymerase (PARP) inhibition is effective in other HR-deficient cancers, but data in mCRC are limited.</p><p><strong>Case description: </strong>We describe four patients with mCRC harboring germline or somatic ATM mutations with high variant allele frequency (VAF). All demonstrated clinical and radiographic benefit from DNA-damaging chemotherapy, including platinum- and topoisomerase-based regimens, exceeding historical controls. In two patients, the addition of PARP inhibitors (PARPi) therapy was associated with sustained disease control. These cases illustrate the potential therapeutic relevance of targeting HR deficiency in ATM-mutated colorectal cancer (CRC).</p><p><strong>Conclusions: </strong>This series underscores the sensitivity of ATM-mutated mCRC to DNA-damaging chemotherapy and highlights the potential role of PARPi. The therapeutic benefit of PARPi in these patients cannot be fully separated from concurrent chemotherapy, and the observed responses are likely to reflect combined effects. Nonetheless, these findings suggest potential synergy and warrant further investigation of PARP inhibition, alone or in combination, in biomarker-selected mCRC populations.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"74"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying risk factors for refractory tyrosine kinase inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.","authors":"Wei Huang, Hejing Ye, Yanlin Zhu, Minmin Huang, Shasha Du, Peixin Tan","doi":"10.21037/cco-25-56","DOIUrl":"10.21037/cco-25-56","url":null,"abstract":"<p><strong>Background: </strong>Tyrosine kinase inhibitors (TKIs) are crucial targeted therapies for non-small cell lung cancer (NSCLC) patients harboring driver gene mutations. TKI-induced interstitial lung disease (TKI-ILD) is uncommon but potentially life-threatening, particularly when there is a poor response to initial corticosteroid treatment. Early identification of patients with refractory TKI-ILD is pivotal for effective management and prognosis. This study aimed to identify risk factors for refractory TKI-ILD.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of clinical records from 71 patients with TKI-ILD at our institution. Refractory TKI-ILD was defined as ILD unresponsive to initial steroid therapy as per therapeutic consensus. We evaluated clinical characteristics, peripheral blood biomarkers, radiological features, and treatment outcomes in both non-refractory and refractory TKI-ILD cases. Risk factors associated with refractory TKI-ILD were examined.</p><p><strong>Results: </strong>Among 71 patients diagnosed with TKI-ILD, 10 (14.1%) developed refractory TKI-ILD. There was a significant disparity in gene mutations (P=0.02) between the two groups. Specifically, anaplastic lymphoma kinase (ALK) rearrangement was more prevalent in the refractory group than in the non-refractory group (40.0% vs. 9.8%). Shortness of breath (100% vs. 55.7%, P=0.02) and dyspnea (60% vs. 11.5%, P=0.001) were more frequent in the refractory group. At TKI-ILD onset, white blood cell count (WBC) [10.58 (8.21-15.38) vs. 6.94 (5.06-10.29) ×109/L, P=0.04] and absolute neutrophil count (ANC) [9.67 (5.71-13.36) vs. 4.53 (3.13-7.85) ×109/L, P=0.04] were significantly high in the refractory TKI-ILD group. Additionally, lactate dehydrogenase (LDH) levels in the refractory group were significantly elevated compared to those in the non-refractory group [422.00 (311.50-518.50) vs. 279.00 (206.00-332.00) U/L, P=0.03]. Radiographic patterns also differed significantly between the two groups (P<0.001), with diffuse alveolar damage (DAD)-like patterns being most prevalent in refractory TKI-ILD patients (80%). Multivariable logistic analysis identified dyspnea, LDH >420 U/L at TKI-ILD onset, and DAD radiographic pattern as independent risk factors for refractory TKI-ILD. The mortality rate of refractory TKI-ILD was 50% (5/10).</p><p><strong>Conclusions: </strong>The mortality rate associated with refractory TKI-ILD is substantial. Dyspnea, LDH >420 U/L at TKI-ILD onset, and DAD radiographic pattern are independent risk factors that may aid in identifying refractory TKI-ILD cases.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"69"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145562902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison of outcomes for patients with localized pancreatic ductal adenocarcinoma receiving neoadjuvant chemotherapy with and without radiation prior to curative-intent resection: an analysis of the National Cancer Database.","authors":"Cade F Bennett, Lauren M Janczewski, Dominic Vitello, Amy Wells, John Abad, Akhil Chawla","doi":"10.21037/cco-25-60","DOIUrl":"10.21037/cco-25-60","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemotherapy has been demonstrated as playing a key role in improving the prognosis of patients receiving surgical resection for local pancreatic ductal adenocarcinoma (PDAC) when compared to up-front surgery. However, the addition of radiation to chemotherapy remains controversial. As such, our study aims to characterize differences in characteristics and outcomes for patients receiving neoadjuvant chemotherapy with radiation (NCR) versus those receiving neoadjuvant chemotherapy alone (NC).</p><p><strong>Methods: </strong>We conducted a retrospective analysis of the National Cancer Database (NCDB) from 2015 to 2020. Patients with localized PDAC (stages I-III) who received neoadjuvant chemotherapy and curative-intent resection were included. Individuals were classified into NC and NCR cohorts based on the treatment they received, with NCR being defined as radiation starting at least 30 days after chemotherapy commencement. Patients receiving adjuvant chemotherapy were included. Univariate models assessed for heterogeneity between cohorts for demographic and tumor characteristics. Multivariate logistic regressions and propensity-matched Cox proportional hazards models assessed for treatment outcomes and survival analysis, respectively. Kaplan-Meier curves were generated to visualize survival between cohorts. Linear regressions quantified utilization trends for these two cohorts as well.</p><p><strong>Results: </strong>This study included 6,472 patients total (NCR: 2,117; NC: 4,355). The NCR patients were younger (64.6 vs. 65.8 years, P<0.001), had differences in tumor primary site (P<0.001), clinical and pathologic staging (P<0.001), and Charleson-Deyo comorbidity score (P<0.001). On multivariate analysis, the NCR cohort had higher odds of tumor downstaging [odds ratio (OR) =2.15, 95% confidence interval (CI): 1.70-2.71, P<0.001], lower odds for pathologic node status (OR =0.42, 95% CI: 0.38-0.48, P<0.001), and lower odds of receiving adjuvant chemotherapy (OR =0.56, 95% CI: 0.49-0.64, P<0.001) but no difference in R0 resection was noted (OR =0.95, 95% CI: 0.80-1.12, P=0.52). Propensity-matched models revealed that NCR was associated with improved overall survival (OS) when compared to NC [hazard ratio (HR) =0.88, 95% CI: 0.80-0.97, P=0.01]. Lastly, the NC cohort had an increase of +166.7 cases/year (P<0.001), but the NCR cohort did not show a significant trend (+35.1 cases/year, P=0.07) from 2015-2020.</p><p><strong>Conclusions: </strong>In patients with localized PDAC who receive curative-intent resection, the addition of radiation to neoadjuvant chemotherapy is associated with improved tumor downstaging, negative node status, and superior survival outcomes. As such, our work supports the use of radiation in the neoadjuvant setting to supplement chemotherapy and highlights further evaluation of its benefits.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"70"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological trends and future projections of bladder and kidney cancer burden in China, 1990-2041: an ecological study.","authors":"Jianxu Yuan, Shengjie Yu, Ji Zheng","doi":"10.21037/cco-25-92","DOIUrl":"https://doi.org/10.21037/cco-25-92","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BCa) and kidney cancer are increasingly significant public health concerns in China. However, comprehensive analyses of their long-term disease burden trends and future projections remain limited. This study analyzed trends in incidence, prevalence, mortality, and disability-adjusted life years (DALYs) for BCa and kidney cancer in China from 1990 to 2021 using Global Burden of Disease (GBD) data, and projected their future burden over the next two decades.</p><p><strong>Methods: </strong>GBD 2021 data were used to evaluate age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life years rate (ASDR). Trends were assessed using Joinpoint (v5.2.0) and R (v4.5.1) to calculate average annual percentage changes (AAPCs). Future burdens (2022-2041) were forecasted with an autoregressive integrated moving average (ARIMA) model.</p><p><strong>Results: </strong>From 1990 to 2021, China experienced significant increases in BCa and kidney cancer incidence, prevalence, mortality, and DALYs. For BCa, ASIR and ASPR increased, while ASMR and ASDR decreased relative to 1990. Kidney cancer showed rising ASIR, ASPR, and ASMR, with ASDR slightly declining. AAPC analysis revealed BCa trends of ASIR (+0.12%), ASPR (+1.59%), ASMR (-1.60%), and ASDR (-1.74%); kidney cancer showed ASIR (+2.39%), ASPR (+3.47%), ASMR (+0.41%), and ASDR (-0.01%). Projections suggest BCa ASIR will keep rising in both sexes by 2041, while ASPR will decline, particularly in males. Kidney cancer ASIR is expected to rise in males but stabilize in females, with ASPR remaining steady.</p><p><strong>Conclusions: </strong>Between 1990 and 2021, China faced growing burdens of BCa and kidney cancer, with notable sex-specific patterns. Projections highlight the need for targeted, age- and sex-specific prevention and control strategies.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 6","pages":"71"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metronomic capecitabine plus aromatase inhibitor as initial therapy in HR-positive HER2-negative metastatic breast cancer: a low-cost and easily implementable option.","authors":"Dana Narvaez, Gerneiva T Parkinson, Stephanie L Graff","doi":"10.21037/cco-25-82","DOIUrl":"https://doi.org/10.21037/cco-25-82","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 6","pages":"79"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing audiometric surveillance in head and neck cancer patients undergoing cisplatin-based chemoradiation.","authors":"Aurora Mirabile, Raffaele Addeo","doi":"10.21037/cco-25-89","DOIUrl":"https://doi.org/10.21037/cco-25-89","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 6","pages":"65"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A bibliometric analysis of 2000-2024 on interventional therapy for liver cancer and tumor immune microenvironment.","authors":"Siqin Liang, Ming Li, Zhiliang Xu, MingMing Luo, Xiaoxiang You, Tinghao Yuan, Xingwen Zhou, Bo Yi, Qiang Tu, Bin Xu","doi":"10.21037/cco-25-83","DOIUrl":"https://doi.org/10.21037/cco-25-83","url":null,"abstract":"<p><strong>Background: </strong>In recent years, the tumor immune microenvironment (TIME) has been gradually emphasized in liver cancer interventional therapy. The present study aimed to evaluate the current research hotspots and developmental trends of TIME from the perspective of bibliometrics.</p><p><strong>Methods: </strong>Publications related to interventional therapy, liver cancer, and TIME were searched on the Web of Science (WOS) Core Collection database for the years 2000-2024, and bibliometric analyses were performed using VOSviewer, CiteSpace, and R \"Bibliometrix\".</p><p><strong>Results: </strong>A bibliometric analysis was conducted on the TIME in liver cancer interventional therapy using data from 2000-2024. The study included 277 articles from 21 regions/countries, with China and the USA leading. The number of articles is increasing annually. Fudan University and Huazhong University of Science and Technology are major research institutions. The Journal of Hepatocellular Carcinoma is the most popular journal, while Hepatology is the most cited. Zheng Chuansheng published the most papers, and Llovet was the most co-cited. Research topics include the mechanism of the TIME in interventional therapy and novel therapies. Emerging hotspots are \"Immunotargeted inhibition\", \"tumor microenvironment\", and \"immunotherapy\".</p><p><strong>Conclusions: </strong>This is the first comprehensive bibliometric study in this field, providing insights into research trends and new directions.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 6","pages":"72"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal evolution of liver cancer etiology in China, 1990-2021: insights from the Global Burden of Disease Study 2021.","authors":"Tao Luo, Senxin Wang, Shangru Yang, Ade Su, Xuean Zhao, Jianqi Qin, Wence Zhou","doi":"10.21037/cco-25-80","DOIUrl":"https://doi.org/10.21037/cco-25-80","url":null,"abstract":"<p><strong>Background: </strong>Primary liver cancer constitutes a significant public health issue in China. The hepatitis B virus (HBV) remains the primary etiological agent of liver cancer, whereas the role of metabolic liver diseases, particularly non-alcoholic steatohepatitis (NASH), is escalating. It is imperative to examine the temporal progression of liver cancer etiology to establish a scientifically grounded framework for developing targeted prevention and control strategies tailored to China's national context. This study aims to utilize the Global Burden of Disease (GBD) 2021 database to systematically evaluate the temporal trends in the liver cancer disease burden in China from 1990 to 2021, analyze the changing contributions of different etiologies [including HBV, hepatitis C virus (HCV), and NASH], assess the impact of sociodemographic factors, and predict future trends, thereby providing a scientific basis for formulating targeted prevention and control strategies tailored to China's national context.</p><p><strong>Methods: </strong>This study performed long-term, large-scale time-series trend comparisons of liver cancer burden in China from 1990 to 2021, focusing on five primary etiologies (HBV, HCV, alcohol consumption, NASH, and other causes) using the GBD 2021 database. The Joinpoint regression model identified trend inflection points, while the age-period-cohort (APC) model elucidated the determinants of disease burden. The Slope Index of Inequality (SII) and Concentration Index (CI) assessed the correlation between various disease burden indicators and the Socio-Demographic Index (SDI), and the Autoregressive Integrated Moving Average (ARIMA) and Bayesian Age-Period-Cohort (BAPC) models were employed for future burden projections.</p><p><strong>Results: </strong>Between 1990 and 2021, the age-standardized incidence rate (ASIR) of liver cancer in China experienced a modest decline [estimated annual percentage change (EAPC) =-0.31], while the total number of cases escalated significantly (+103.91%), with aging contributing to a 141.91% rise in disability-adjusted life years (DALYs). The incidence of HBV-associated liver cancer diminished dramatically (ASIR EAPC =-0.55), whereas NASH-associated liver cancer escalated rapidly (ASIR EAPC =0.73). China, categorized as a medium-to-high SDI region, exhibits a greater incidence of liver cancer and various etiologies of the disease compared to other regions with equivalent SDI levels. Future forecasts indicate that liver cancer connected with alcohol consumption and NASH may persist in increasing.</p><p><strong>Conclusions: </strong>The prevention and management of HBV infection in China have been efficient; however, the prevalence of metabolic illnesses in the etiology of liver cancer has escalated, and aging alongside population expansion has positively contributed to the increasing burden of liver cancer.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 6","pages":"73"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of cardiac markers in patients with breast cancer receiving antineoplastic treatment: a systematic review.","authors":"Tiago Nunes da Silva Soares, Thaís Moura Gascón, Fernando Luiz Affonso Fonseca, Neif Murad, Samantha Sanches de Carvalho, Glaucia Luciano da Veiga, Beatriz da Costa Aguiar Alves, Edimar Cristiano Pereira","doi":"10.21037/cco-24-136","DOIUrl":"https://doi.org/10.21037/cco-24-136","url":null,"abstract":"<p><strong>Background: </strong>Cardiac markers are important in the diagnosis of heart and coronary insufficiency, it is through them that they can measure the damage to cardiac fibers resulting from these diseases. Recent research has shown that the levels of biomarkers are altered who have neoplasms under chemotherapy treatment without these patients having any clinical manifestations. The research was to conduct a systematic review of the main cardiac biomolecular markers in scientific publications bases and to verify how their levels present in individuals with breast cancer, as well as to analyze the influence of antineoplastic treatment in the circular levels of these markers resulting from the effects of cardiac damage on patient therapy and which are good predictors of cardiovascular diseases related to chemotherapy treatment.</p><p><strong>Methods: </strong>Medline, Lilacs and Cochrane and in these databases, systematic searches of publications were carried out between the years 2010 and 2020 using the descriptors \"Mesh\" or the equivalent in the chosen database. Studies that evaluated the following cardiac biomarkers: troponin, pro-type B natriuretic peptide (proBNP)/N-terminal pro-BNP (NT-proBNP), myoglobin, creatine kinase-MB fraction, fibrinogen, and D-dimer.</p><p><strong>Results: </strong>At the end, 31 published articles were obtained for analysis in which cardiac markers ultra-sensitive troponin I and T, myoglobin, and NT-proBNP showed to be the best predictors of cardiotoxicity for breast cancer patient under chemotherapy.</p><p><strong>Conclusions: </strong>The ultra-sensitive cardiac markers troponin I and T, NT-proBNP and myoglobin, were the ones that provided the best biomarkers in detecting cardiotoxicity, requiring continuous research and research for cardiotoxic biomarkers.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":"14 6","pages":"76"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ROS1 therapy among patients with advanced non-small cell lung cancer: an endless road to rediscover?","authors":"Gilson Gabriel Viana Veloso, Nathalia Gimenes Afonso, Carlos Gil Ferreira","doi":"10.21037/cco-25-79","DOIUrl":"10.21037/cco-25-79","url":null,"abstract":"","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":" ","pages":"80"},"PeriodicalIF":2.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145803310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}